Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis

Epilepsy is a common neurological disease with a high incidence in pediatrics[1]. Multiple anti-seizure medications (ASMs) have been developed for patients with epilepsy, however, in approximately 20% of pediatric patients, current treatment fails to adequately control their seizures[2]. Thus, novel ASMs must be developed for pediatric patients.

11
JUN
0